Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DECLARE-TIMI 58: Participants' baseline characteristics.

Itamar Raz1, Ofri Mosenzon1, Marc P Bonaca2

  • 1Diabetes Unit, Department of Internal Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel.

Diabetes, Obesity & Metabolism
|January 12, 2018
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

How Common Is Hypercortisolism in Patients With Hypertension? Risk Factors, Epidemiology, and Making a Diagnosis.

Diabetes, obesity & metabolism·2026
Same author

Implementing SGLT2 Inhibitor Therapy in Line with the New NICE Guidelines for Type 2 Diabetes Management.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026
Same author

Long-Term Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Peripheral Artery Disease and Type 2 Diabetes.

Journal of the American Heart Association·2026
Same author

The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities.

European cardiology·2026
Same author

Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.

Journal of the American Heart Association·2026
Same author

Role of systemic and epicardial adipose tissue in cardiometabolic disease.

Nature reviews. Cardiology·2026

The Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58) trial assessed baseline characteristics of patients with type 2 diabetes. This large study provides data on cardiovascular outcomes for patients with established cardiovascular disease or multiple risk factors.

Area of Science:

  • Cardiology
  • Endocrinology
  • Clinical Trials

Background:

  • Type 2 diabetes is a major risk factor for cardiovascular disease (CVD).
  • Sodium-glucose cotransporter-2 (SGLT2) inhibitors, like dapagliflozin, are used to manage type 2 diabetes.
  • Assessing cardiovascular outcomes in diverse diabetic populations is crucial.

Purpose of the Study:

  • To describe the baseline characteristics of participants in the DECLARE-TIMI 58 trial.
  • To establish the profile of patients randomized for cardiovascular outcome assessment with dapagliflozin.
  • To understand the characteristics of patients with type 2 diabetes and either established CVD or multiple risk factors for CVD.

Main Methods:

  • The DECLARE-TIMI 58 trial randomized 17,160 patients with type 2 diabetes.
Keywords:
CVOTsSGLT2 inhibitorscardiovascular outcomesdapagliflozintype 2 diabetes

Related Experiment Videos

  • Participants received either dapagliflozin (10 mg/day) or a matching placebo.
  • Baseline demographic and clinical characteristics were analyzed.

    • Main Results:

    • The study population had a mean age of 63.8 years, with 62.6% males.
    • Participants had a mean diabetes duration of 11.8 years and a mean HbA1c of 8.3%.
    • 40.6% had established CVD, while 59.4% had multiple risk factors for CVD.

    Conclusions:

    • The DECLARE-TIMI 58 trial enrolled a broad population of patients with type 2 diabetes.
    • Baseline characteristics differed between patients with CVD and those with multiple risk factors.
    • The trial is poised to yield significant data on dapagliflozin's effect on cardiovascular outcomes.